计划状态
活跃，非招募阶段
第二阶段允许先接受免疫治疗
是CRC 指导的试验
是药物
Cetuximab Injection [Erbitux], HLX208标签
MSS/ MMRp评论
For BRAF mutant CRC, after failure of first line treatment. Targeted therapy.
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer (and head and neck cancer). It is mainly used in KRAS wild type metastatic CRC.
HLX208 – trial medication that is a BRAF V600E Inhibitor
| 地点 | 位置状态 |
|---|---|
| 中国 | |
|
Fudan University Affiliated Oncology Hospital 上海 |
活跃，非招募 |
纳入标准
纳入标准
Age>=18Y
Good Organ Function
Expected survival time ≥ 3 months
Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed first line treatment
ECOG score 0-1;
排除标准
排除标准：
arm 1 ： Previous treatment with BRAF inhibitors or MEK inhibitors
Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
Active clinical severe infection;
A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
